Diego Ripamonti

3.9k total citations
62 papers, 1.2k citations indexed

About

Diego Ripamonti is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Diego Ripamonti has authored 62 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Infectious Diseases, 39 papers in Virology and 12 papers in Epidemiology. Recurrent topics in Diego Ripamonti's work include HIV/AIDS drug development and treatment (40 papers), HIV Research and Treatment (39 papers) and HIV/AIDS Research and Interventions (32 papers). Diego Ripamonti is often cited by papers focused on HIV/AIDS drug development and treatment (40 papers), HIV Research and Treatment (39 papers) and HIV/AIDS Research and Interventions (32 papers). Diego Ripamonti collaborates with scholars based in Italy, United States and France. Diego Ripamonti's co-authors include Franco Maggiolo, Fredy Suter, Fredy Suter, Claudio Arici, Annapaola Callegaro, Marco Rizzi, Giampietro Gregis, Monica Airoldi, Dario Cattaneo and Veronica Ravasio and has published in prestigious journals such as Brain, Clinical Infectious Diseases and Scientific Reports.

In The Last Decade

Diego Ripamonti

61 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Diego Ripamonti Italy 21 969 630 358 330 155 62 1.2k
Elena Seminari Italy 20 847 0.9× 457 0.7× 297 0.8× 239 0.7× 103 0.7× 87 1.2k
Duncan Churchill United Kingdom 17 720 0.7× 543 0.9× 241 0.7× 284 0.9× 46 0.3× 50 1.1k
José Antonio Iribarren Spain 20 1.1k 1.1× 731 1.2× 593 1.7× 312 0.9× 281 1.8× 84 1.5k
Susan L. Ford United States 22 1.5k 1.6× 1.1k 1.7× 391 1.1× 215 0.7× 97 0.6× 56 1.8k
Teresa Bini Italy 17 622 0.6× 442 0.7× 278 0.8× 313 0.9× 53 0.3× 65 962
Herman G. Sprenger Netherlands 13 624 0.6× 391 0.6× 223 0.6× 396 1.2× 50 0.3× 41 994
Michèle Grappin France 17 624 0.6× 306 0.5× 387 1.1× 384 1.2× 308 2.0× 33 1.0k
JN Bruun Norway 5 937 1.0× 625 1.0× 380 1.1× 300 0.9× 51 0.3× 6 1.1k
Jonathan Ainsworth United Kingdom 18 792 0.8× 515 0.8× 492 1.4× 236 0.7× 37 0.2× 44 1.2k
Scott Hammer United States 14 1.3k 1.4× 1.1k 1.8× 280 0.8× 493 1.5× 75 0.5× 23 1.6k

Countries citing papers authored by Diego Ripamonti

Since Specialization
Citations

This map shows the geographic impact of Diego Ripamonti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diego Ripamonti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diego Ripamonti more than expected).

Fields of papers citing papers by Diego Ripamonti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diego Ripamonti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diego Ripamonti. The network helps show where Diego Ripamonti may publish in the future.

Co-authorship network of co-authors of Diego Ripamonti

This figure shows the co-authorship network connecting the top 25 collaborators of Diego Ripamonti. A scholar is included among the top collaborators of Diego Ripamonti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diego Ripamonti. Diego Ripamonti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Calcagno, Andrea, Jessica Cusato, Paola Cinque, et al.. (2024). Serum and CSF biomarkers in asymptomatic patients during primary HIV infection: a randomized study. Brain. 147(11). 3742–3750. 4 indexed citations
2.
Comi, Laura, et al.. (2024). SC-13 Impact of PrEP cost on prophylaxis initiation in an Italian centre. A80–A81. 3 indexed citations
3.
Bruzzesi, Elena, Arianna Gabrieli, Davide Paolo Bernasconi, et al.. (2023). HIV‐DNA decrease during treatment in primary HIV‐1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial. Journal of Medical Virology. 95(9). e29114–e29114. 5 indexed citations
4.
Antinori, Andrea, Alessandra Vergori, Diego Ripamonti, et al.. (2023). Investigating coping and stigma in people living with HIV through narrative medicine in the Italian multicentre non-interventional study DIAMANTE. Scientific Reports. 13(1). 17624–17624. 3 indexed citations
5.
Ripamonti, Diego, Giovanni Mazzola, Pietro Colletti, et al.. (2022). Perceptions of U = U Among Italian Infectious Diseases Specialists: A Nationwide Survey on Providers' Attitudes Toward the Risk of HIV Transmission in Virologically Suppressed Patients. AIDS Research and Human Retroviruses. 38(11). 847–855. 2 indexed citations
6.
Taramasso, Lucia, Niccolò Riccardi, Filippo Del Puente, et al.. (2017). Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis?. AIDS Research and Human Retroviruses. 34(2). 168–170. 1 indexed citations
7.
Hopkins, Chris, Eamon Duffy, Daniel Lee, et al.. (2017). Association of the HLA-B*53:01 Allele With Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome During Treatment of HIV Infection With Raltegravir. Clinical Infectious Diseases. 64(9). 1198–1203. 30 indexed citations
8.
Marinaro, Letizia, Andrea Calcagno, Diego Ripamonti, et al.. (2016). Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting. Journal of Clinical Virology. 87. 30–36. 4 indexed citations
9.
Andreoni, Massimo, Andrea Giacometti, Ivana Maida, et al.. (2012). HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications.. PubMed. 16(11). 1473–83. 42 indexed citations
10.
Cattaneo, Dario, Diego Ripamonti, Sara Baldelli, et al.. (2011). Limited sampling strategies for the estimation of atazanavir daily exposure in HIV‐infected patients. Fundamental and Clinical Pharmacology. 27(2). 216–222. 3 indexed citations
11.
Leone, Sebastiano, Giampaolo Quinzan, Giuliana Cologni, et al.. (2011). Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort. Infection. 39(1). 13–20. 37 indexed citations
12.
Cattaneo, Dario, Diego Ripamonti, Cristina Gervasoni, et al.. (2011). Limited Sampling Strategies for the Estimation of Raltegravir Daily Exposure in HIV‐Infected Patients. The Journal of Clinical Pharmacology. 52(3). 440–445. 15 indexed citations
13.
Torti, Carlo, Mattia Prosperi, Davide Motta, et al.. (2011). Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy. Clinical Microbiology and Infection. 18(5). 449–458. 63 indexed citations
14.
Maggiolo, Franco, Claudio Arici, Monica Airoldi, et al.. (2007). Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort. Journal of Antimicrobial Chemotherapy. 59(3). 569–572. 13 indexed citations
15.
Maggiolo, Franco, Diego Ripamonti, Monica Airoldi, et al.. (2007). Resistance Costs and Future Drug Options of Antiretroviral Therapies: Analysis of the Role of NRTIs, NNRTIs, and PIs in a Large Clinical Cohort. HIV Clinical Trials. 8(1). 9–18. 7 indexed citations
16.
Ripamonti, Diego, Dario Cattaneo, Franco Maggiolo, et al.. (2007). Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS. 21(18). 2409–2415. 77 indexed citations
17.
Ripamonti, Diego, et al.. (2004). New Times for an Old Disease: Intracranial Mass Lesions Caused by Mycobacterium tuberculosis in 5 HIV-Negative African Immigrants. Clinical Infectious Diseases. 39(5). e35–e45. 10 indexed citations
18.
Maggiolo, Franco, et al.. (2004). Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells. AIDS. 18(3). 439–446. 104 indexed citations
19.
Ripamonti, Diego, María Rízzí, Franco Maggiolo, Claudio Arici, & Fredy Suter. (2003). Resolution of Lymphocytic Interstitial Pneumonia in a Human Immunodeficiency Virus-infected Adult Following the Start of Highly Active Antiretroviral Therapy. Scandinavian Journal of Infectious Diseases. 35(5). 348–351. 3 indexed citations
20.
Arici, Claudio, Diego Ripamonti, Franco Maggiolo, et al.. (2002). Factors associated with the failure of HIV-positive persons to return for scheduled medical visits. HIV Clinical Trials. 3(1). 52–57. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elena Seminari Breakdown of academic impact, for papers by Duncan Churchill Breakdown of academic impact, for papers by José Antonio Iribarren Breakdown of academic impact, for papers by Susan L. Ford Breakdown of academic impact, for papers by Teresa Bini Breakdown of academic impact, for papers by Herman G. Sprenger Breakdown of academic impact, for papers by Michèle Grappin Breakdown of academic impact, for papers by JN Bruun Breakdown of academic impact, for papers by Jonathan Ainsworth Breakdown of academic impact, for papers by Scott Hammer
Rankless by CCL
2026